Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2025)

Alnylam Pharmaceuticals (ALNY) posted Long-Term Debt Repayments of $52.3 million for Q4 2025, down 95.29% on a QoQ basis from $1.1 billion in Q3 2025.

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2025) Analysis & Trends

Alnylam Pharmaceuticals' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $52.3 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 7.64 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 52.30 Mn
Dec 31, 2025 52.30 Mn
Sep 30, 2025 1.11 Bn
Sep 30, 2025 1.11 Bn